Occupier lunch: precision execution of bispecifics at scale from design to delivery

  • Wednesday, 23 March 2022, 12:30 PM to 1:30 PM

Occupiers are invited to a face-to-face lunch and learn session with Lonza, presented by Lisa Prendergast, Ph.D.

Heavy-light chain mispairing is one of the major concerns for producing bispecific antibodies. While solutions to Heavy-light chain mispairing exist, many require extensive adaptation of downstream processes. At Lonza, they have found a way to stabilise the interaction between the HC and LC which essentially removes the mispairing problem.  bYlok™ technology is a design engineering approach that solves this whist retaining molecule’s closer-to-nature structure and simplified downstream purification. The presentation will also include how GS System® is set to support development of bispecific molecules by streamlining vector construction process and improved titers using GS piggyBac® transposon system.

Dr. Lisa Prendergast is the Associate Director of Expression System Sciences in Licensing at Lonza and Subject Matter Expert for Molecular Biology for Lonza’s GS Gene Expression System®. Dr. Prendergast has extensive discovery research experience from her postdoctoral work in Ireland, France and the UK.  As a Senior Research Associate and Lead Biologist for Cancer Research UK she worked within target validation for early stage oncology drug discovery programmes.  Prior to joining Lonza she supported the UKHSA pandemic response with the scale up of the UK National COVID-19 testing infrastructure. She holds a Ph.D. in Biochemistry from the National University of Ireland, Galway.

Lisa will be available in the Atrium from 11.00am on 23rd March and would be delighted to meet with other occupiers. If you wish to schedule a slot to meet with her for a specific time, then please email lisa.prendergast@lonza.com.

This is a live event and lunch will be provided. There is no need to book.


Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.